Aaron Mitchell, MD, MPH

Assistant Attending

Aaron Mitchell, MD, MPH

Office Phone

646-888-8155

Dr. Aaron P. Mitchell is an oncologist and health services researcher. He received his clinical training at Duke University Hospital (residency) and at University of North Carolina at Chapel Hill (fellowship). He received an MPH in epidemiology from the University of North Carolina and has completed a postdoctoral research fellowship at UNC’s Cecil G. Sheps Center for Health Services research. Dr. Mitchell’s research focuses on the interaction between financial incentives and physician behavior. He seeks to understand how changes to current reimbursement models for oncology services may be used to achieve better patient outcomes and reduce low-value care. Specifically, he is leading a study to assess the impact of Medicare Accountable Care Organizations on cancer cost and quality outcomes. He previously led an ASCO-funded observational study to assess oncologists’ responsiveness to reimbursement incentives in using high-cost, low-efficacy drugs, and he continues to study physician-level factors associated with use of low-value treatments. His clinical interests are in genitourinary malignancies; he holds a co-appointment in the Genitourinary Oncology Service, treating patients with prostate and bladder cancer.

Publications


  1. 1) Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. 2018 Jun 1;178(6):854-856. doi: 10.1001/jamainternmed.2018.0776. PubMed PMID: 29630687.

  2. 2) Mitchell AP, Basch EM, Dusetzina SB. Financial Relationships With Industry Among National Comprehensive Cancer Network Guideline Authors. JAMA Oncol. 2016 Dec 1;2(12):1628-1631. doi: 10.1001/jamaoncol.2016.2710. PubMed PMID: 27561170.

  3. 3) Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. J Oncol Pract. 2015 Nov;11(6):491-7. doi: 10.1200/JOP.2015.004929. Epub 2015 Sep 1. PubMed PMID: 26330533.

  4. 4) Mitchell A, Muluneh B, Patel R, Basch E. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics. J Oncol Pharm Pract. 2017 Jan 1:1078155217719585. doi: 10.1177/1078155217719585. [Epub ahead of print] PubMed PMID: 28714357.

  5. 5) Mitchell AP, Hirsch BR, Harrison MR, Abernethy AP, George DJ. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):e159-66. doi: 10.1016/j.clgc.2014.12.017. Epub 2014 Dec 31. PubMed PMID: 25770767.

View a full listing of Aaron Mitchell’s journal articles.